Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board

Kalaris Therapeutics, Inc. (NASDAQ:KLRS) is one of the 10 High Growth Stocks Insiders Are Buying.

On July 6, 2026, Kalaris Therapeutics, Inc. (NASDAQ:KLRS) announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. In connection with Keating’s appointment, Morana Jovan-Embiricos is stepping down from the Board.

David Hallal, Chairman of the Kalaris Board of Directors, said Keating brings strategic, operational, and legal expertise across multiple therapeutic areas and development stages. Hallal also thanked Jovan-Embiricos for her service over the past year, noting her role in helping Kalaris advance TH103 and evolve as a public biotech company.

Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board

disease-4392163_1920

On June 15, 2026, TD Cowen analyst Tara Bancroft initiated coverage of Kalaris Therapeutics with a Buy rating and no price target. Bancroft said the company’s TH103 is a “differentiated” anti-VEGF by design through more potent VEGF inhibition and retinal retention. Bancroft added that early data in wet age-related macular degeneration suggest even a single dose can achieve competitive efficacy versus the standard of care.

Kalaris Therapeutics, Inc. (NASDAQ:KLRS) develops and commercializes treatments for prevalent retinal diseases.

While we acknowledge the risk and potential of KLRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than KLRS and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1